Vraylar Approval History
Vraylar (cariprazine) is a dopamine D3/D2 receptor partial agonist atypical antipsychotic for the:
- treatment of schizophrenia in adults
- acute treatment of manic or mixed episodes associated with bipolar I disorder in adults
- treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.
Development History and FDA Approval Process for Vraylar
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.